Avid Bioservices, Inc. (CDMO) Stock

About Avid Bioservices, Inc.

Avid Bioservices, Inc. operates as a Contract Development and Manufacturing Organization (CDMO), specializing in the development and CGMP-compliant production of biopharmaceutical drug substances. Their core expertise lies in compounds derived from mammalian cell culture, providing both clinical and commercial scale manufacturing solutions. The company is proficient in producing critical therapeutics such as monoclonal antibodies and recombinant proteins. Beyond manufacturing, their comprehensive service portfolio encompasses CGMP manufacturing for drug substances, bulk packaging, rigorous release and stability testing, and essential regulatory submission and support. Additionally, Avid Bioservices offers a range of process development services, including the optimization of upstream and downstream processes, alongside the development, testing, and characterization of analytical methods. Avid Bioservices primarily serves clients within the biotechnology and biopharmaceutical industries. The company, which was originally incorporated in 1981, was known as Peregrine Pharmaceuticals, Inc. before officially rebranding to Avid Bioservices, Inc. in January 2018. Its corporate headquarters are situated in Tustin, California.

Avid Bioservices, Inc. is headquartered in US.

Avid Bioservices, Inc. (CDMO) stock trades at $12.49 with a market capitalization of $798.90M. The stock is valued at a price-to-earnings (P/E) ratio of -5.60, price-to-book of 12.96, price-to-sales of 5.71. Over the past 52 weeks the stock has ranged between $5.90 and $12.51, and currently trades at its 52-week high.

On profitability, Avid Bioservices, Inc. generates a return on equity (ROE) of -112.44%, return on capital employed of -7.02%, an operating margin of -13.35%, a net profit margin of -100.60%.

Official website: www.avidbio.com